Valuation: IDEAYA Biosciences, Inc.

Market Cap 3.08B 2.76B 2.54B 2.3B 4.3B 293B 4.38B 30.3B 12.16B 154B 11.57B 11.33B 486B P/E 2026 *
-6.89x
P/E 2027 * -7.43x
Enterprise Value 2.09B 1.87B 1.72B 1.56B 2.92B 199B 2.97B 20.56B 8.25B 105B 7.85B 7.69B 330B EV / Sales 2026 *
51x
EV / Sales 2027 * 17x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
10-23 IDEAYA Biosciences, Inc. Announces Updated Clinical Results For IDE849 In Relapsed Small Cell Lung Cancer And Other Neuroendocrine Carcinomas CI
10-19 IDEAYA Biosciences, Inc. And Servier Announce Updated Clinical Data From Three Ongoing Studies Evaluating Darovasertib In Metastatic And Primary Uveal Melanoma CI
10-19 Ideaya's PRMT5, MAT2A Programs Draw Investor Focus, RBC Says MT
10-16 William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating MT
09-28 IDEAYA Biosciences, Inc. Announces Promotion of Michael White from Chief Scientific Officer to President, Research and Development, Effective September 28, 2026 CI
09-14 IDEAYA Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-11 IDEAYA Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 01:40 PM
09-09 IDEAYA Biosciences, Inc. and Servier Dose First Patient in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Uveal Melanoma CI
09-09 Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial MT
08-31 IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer CI
08-31 IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy MT
08-19 Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial MT
08-19 IDEAYA Biosciences, Inc. Enters Clinical Collaboration With Genentech To Evaluate IDE892 In Combination With RG6620 In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer CI
1 day-2.83%
1 week-7.92%
Current month-16.81%
1 month-16.81%
3 months-12.20%
6 months+9.83%
Current year-7.55%
1 week 31.7
Extreme 31.7
35.31
1 month 31.7
Extreme 31.7
38.56
Current year 26.81
Extreme 26.81
42.68
1 year 26.81
Extreme 26.81
42.68
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 01/06/2015
Director of Finance/CFO 51 01/05/2025
Chief Tech/Sci/R&D Officer 59 21/11/2022
Director TitleAgeSince
Chairman 51 17/06/2026
Chairman 67 -
Director/Board Member 71 01/10/2015
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Exercice

Chief Executive Officer

79,014 0.0902%
07/07/26 Exercice

Controller/Auditor

28,650 0.0327%
16/06/26 Free

Director

20,000 0.0228%
Change 5-day change 1-year change 3-year change Capi.($)
-2.83%-7.92%+1.14%+24.07% 3.08B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.02%+5.99%+43.19%+188.10% 39.74B
Weighted average by Cap. +0.15%+5.34%+48.13%+184.87%

Financials

2026 *2027 *
Net sales 41.01M 36.73M 33.79M 30.61M 57.22M 3.89B 58.29M 403M 162M 2.05B 154M 151M 6.46B 118M 106M 97.45M 88.3M 165M 11.23B 168M 1.16B 467M 5.91B 444M 435M 18.63B
Net income -434M -389M -358M -324M -606M -41.22B -617M -4.27B -1.71B -21.68B -1.63B -1.59B -68.38B -424M -380M -350M -317M -592M -40.3B -603M -4.17B -1.67B -21.2B -1.59B -1.56B -66.85B
Net Debt -991M -888M -817M -740M -1.38B -94.11B -1.41B -9.74B -3.91B -49.51B -3.72B -3.64B -156B -1.07B -956M -879M -797M -1.49B -101B -1.52B -10.49B -4.21B -53.31B -4.01B -3.92B -168B
Projected Income Statement - Annual - IDEAYA Biosciences, Inc.
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
30/10/26 $31.96 -2.83% 838,033
29/10/26 $32.89 -3.15% 1,623,974
28/10/26 $33.96 +1.37% 994,243
27/10/26 $33.50 +1.89% 1,000,833
26/10/26 $32.88 -5.27% 1,188,206
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - IDEAYA Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
31.96USD
Average target price
51.92USD
Spread / Average Target
+62.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IDEAYA Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IDYA Stock